PDCD1 and head and neck squamous cell carcinoma: Expansion cohort performed by Chow et al. [55] to assess the antitumor activity of pembrolizumab, a highly selective monoclonal antibody that blocks the interaction between PD-1 and its ligands, in patients with recurrent and/or metastatic HNSCC.